International Prostate Cancer Update 2019

Salvage Lymph Node Dissection for Prostate Cancer

Paul D. Maroni, MD, argues that salvage pelvic lymph node dissection is feasible, safe, and may be efficacious in the treatment of oligometastatic prostate cancer. He reviews data suggesting that this method can optimize locoregional control, limit the risk of distant progression, avoid the necessity for immediate androgen deprivation therapy (ADT), and improve cancer-specific survival.

Read More

Telehealth in Urology

James Sylora, MD, discusses the increasing demand for telemedicine services and the advantages it provides to patients and clinical practices. He outlines steps, as well as practical and legal considerations, for establishing a telemedicine protocol in a practice.

Read More

Diet and Prostate Cancer- Now What?

J. Kellogg Parsons, MD, MHS, FACS, reviews the Men’s Eating and Living (MEAL) study, a randomized, phase III clinical trial testing diet intervention in prostate cancer patients under active surveillance. He describes the trial methodology and design, as well as clinical progression and quality of life outcomes.

Read More

3DBiopsy™: Transperineal Mapping Biopsy in 2019

Nelson N. Stone, MD, discusses the need for adequate and accurate prostate cancer identification techniques, especially when selecting patients for active surveillance. He then reviews an emerging transperineal prostate mapping biopsy system that could be an improved tool for fusion biopsy, replace current transrectal biopsy devices, and better detect and localize lesions.

Read More

New Considerations for Oligometastatic Prostate Cancer

Raoul S. Concepcion, MD, FACS, discusses the management of patients with oligometastatic prostate cancer. Currently, there is no standard definition of what defines oligometastatic.  Additionally, questions remain about the handling of the primary tumor in this setting, as well as whether therapy directed at the primary has a long term benefit in overall survival.

Read More


Steven E. Finkelstein, MD, FACRO, discusses the increasing prevalence of brachytherapy as an option for prostate cancer patients in need of radiation therapy, specifically in the recurrent space. Additionally, he addresses the limitations of the technique and the lack of studies directly comparing brachytherapy to other options.

Read More

Join the GRU Community

- Why Join? -